{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-214976","form_type":"8-K","ticker":"NKTR","cik":"0000906709","company_name":"NEKTAR THERAPEUTICS","filed_at":"2026-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.914871+00:00","generated_at":"2026-05-14T21:17:49.739425+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nektar enters $150M ATM equity agreement; appoints Linda Rubinstein as interim CFO","bullets":["Equity Distribution Agreement with Guggenheim Securities and H.C. Wainwright for up to $150M of common stock in at-the-market offerings.","Sandra Gardiner retiring as interim CFO effective May 15, 2026; Linda Rubinstein of FLG Partners will succeed her.","Rubinstein has over 35 years experience, raised >$5B in financings, and previously CFO of Adverum Biotechnologies.","Shares may be sold through ordinary brokers' transactions on Nasdaq at market prices; 3.0% commission fee to agents."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-214976","json":"https://secwatch.observer/filing/0001193125-26-214976.json","markdown":"https://secwatch.observer/filing/0001193125-26-214976.md","text":"https://secwatch.observer/filing/0001193125-26-214976.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/d159808d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:17:49.739425+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c637163245","claim":"Linda Rubinstein was appointed as interim Chief Financial Officer at NEKTAR THERAPEUTICS.","evidence_excerpt":"Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm","confidence":0.95},{"claim_id":"eb697dfc1c","claim":"Sandra Gardiner departed as interim Chief Financial Officer at NEKTAR THERAPEUTICS.","evidence_excerpt":"On May 7, 2026, the Company announced that Sandra Gardiner will be retiring and stepping down as interim Chief Financial Officer of the Company, effective May 15, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm","confidence":0.95},{"claim_id":"601bef46dca020c84af9e47aeae1c7ade3ca6330","claim":"NEKTAR THERAPEUTICS entered into Equity Distribution Agreement with Guggenheim Securities, LLC and H.C. Wainwright & Co., LLC valued at $150,000,000 (effective 2026-05-08).","evidence_excerpt":"On May 8, 2026, Nektar Therapeutics (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”) having an aggregate offering price of up to $150,000,000 (the “Shares”), through Guggenheim Securities and Wainwright as its sales agents.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001104659-26-068521","ticker":"FDXF","company_name":"FedEx Freight Holding Company, Inc.","filed_at":"2026-06-01T10:46:03+00:00","headline":"FedEx Freight completes spin-off from FedEx; $600M drawn, new board and executives appointed","event_type":"other_material","sec_items":["1.01","2.03","3.03","5.03","5.01","5.02","5.05","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: executive_change","same SEC item: 1.01, 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068521","json":"https://secwatch.observer/filing/0001104659-26-068521.json","markdown":"https://secwatch.observer/filing/0001104659-26-068521.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2082247/000110465926068521/0001104659-26-068521-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2082247/000110465926068521/tm2615735d2_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm","comparable_excerpt":"each of John A. Smith, R. Brad Martin, Jeffrey A. Davis, Donald E. Frieson, Stephen E. Gorman, Robert A. King, Cindy J. Miller, Amy J. Salcido, and Samantha M. Smith was appointed to the Board","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2082247/000110465926068521/0001104659-26-068521-index.htm"}},{"accession":"0001829126-26-005831","ticker":"FXAC","company_name":"FortuneX Acquisition Corp","filed_at":"2026-05-29T21:32:49+00:00","headline":"FortuneX Acquisition closes IPO of 8.625M units at $10/unit, raising $86.25M gross","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: executive_change","same SEC item: 1.01, 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-005831","json":"https://secwatch.observer/filing/0001829126-26-005831.json","markdown":"https://secwatch.observer/filing/0001829126-26-005831.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2121703/000182912626005831/0001829126-26-005831-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2121703/000182912626005831/fortunexacq_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm","comparable_excerpt":"Effective May 19, 2026, in connection with the effectiveness of the Company’s Registration Statement, Becky Fallon, Sean Michael Deegan, and Robert Labbe became members of the board of directors (the “Board”) of the Company.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2121703/000182912626005831/0001829126-26-005831-index.htm"}},{"accession":"0001171843-26-003809","ticker":"CRMT","company_name":"AMERICAS CARMART INC","filed_at":"2026-05-29T21:30:17+00:00","headline":"America's Car-Mart forms special committee for strategic alternatives; appoints new independent director","event_type":"other_material","sec_items":["1.01","5.02","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 1.01, 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-003809","json":"https://secwatch.observer/filing/0001171843-26-003809.json","markdown":"https://secwatch.observer/filing/0001171843-26-003809.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/799850/000117184326003809/0001171843-26-003809-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/799850/000117184326003809/f8k_052926.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm","comparable_excerpt":"On May 22, 2026, the Board increased the size of the Board from nine members to ten members and appointed Adam Paul as an independent director, effective immediately.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/799850/000117184326003809/0001171843-26-003809-index.htm"}},{"accession":"0001493152-26-026603","ticker":"PUBC","company_name":"Purebase Corp","filed_at":"2026-06-01T19:42:27+00:00","headline":"Purebase to receive 20% of net proceeds from CoreTer mining deal; waives corporate opportunities","event_type":"other_material","sec_items":["1.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026603","json":"https://secwatch.observer/filing/0001493152-26-026603.json","markdown":"https://secwatch.observer/filing/0001493152-26-026603.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1575858/000149315226026603/0001493152-26-026603-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1575858/000149315226026603/form8-k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 8, 2026, Nektar Therapeutics (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”) having an aggregate offering price of up to $150,000,000 (the “Shares”), through Guggenheim Securities and Wainwright as its sales agents.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm","comparable_excerpt":"On May 26, 2026, Purebase Corporation (the “Company”) entered into a binding Memorandum of Understanding (the “MOU”) with CoreTer LLC, a Nevada limited liability company (“CoreTer”), pursuant to which the Company will be entitled to 20% of the net proceeds received by CoreTer under an Exclusive Mining Option and Development Agreement, dated March 19, 2026, between CoreTer and Dexter Mining LLC.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1575858/000149315226026603/0001493152-26-026603-index.htm"}},{"accession":"0001493152-26-026544","ticker":"LIXT","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2026-06-01T12:55:34+00:00","headline":"Lixte Biotechnology pivots to AI energy infrastructure; appoints Denham Capital founder to board","event_type":"other_material","sec_items":["5.02","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026544","json":"https://secwatch.observer/filing/0001493152-26-026544.json","markdown":"https://secwatch.observer/filing/0001493152-26-026544.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/0001493152-26-026544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/form8-k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm","comparable_excerpt":"On May 29, 2026, the Board of Directors (the “Board”) of Lixte Biotechnology Holdings, Inc., (the “Company”), appointed Stuart D. Porter to serve as a member of the Board, effective May 29, 2026 with a term expiring at the Company’s 2026 Annual Meeting of Stockholders.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/0001493152-26-026544-index.htm"}},{"accession":"0001193125-26-249692","ticker":"ELOX","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2026-06-01T11:00:19+00:00","headline":"Eloxx Pharma: 1-for-11 reverse stock split effective May 29; appoints two independent directors","event_type":"other_material","sec_items":["3.02","3.03","5.03","5.02","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-249692","json":"https://secwatch.observer/filing/0001193125-26-249692.json","markdown":"https://secwatch.observer/filing/0001193125-26-249692.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/0001193125-26-249692-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/d261568d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm","comparable_excerpt":"the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed Stephen W. Webster and Nina Kjellson to fill vacancies on the Board","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526249692/0001193125-26-249692-index.htm"}},{"accession":"0000947871-26-000585","ticker":"MVST","company_name":"Microvast Holdings, Inc.","filed_at":"2026-05-28T21:26:49+00:00","headline":"Microvast CEO converts $25M loan to equity; CAO Eric Garcia departs","event_type":"other_material","sec_items":["5.02","8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000947871-26-000585","json":"https://secwatch.observer/filing/0000947871-26-000585.json","markdown":"https://secwatch.observer/filing/0000947871-26-000585.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760689/000094787126000585/0000947871-26-000585-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760689/000094787126000585/ss6384648_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm","comparable_excerpt":"On May 27, 2026, Eric N. Garcia ceased to be employed as Chief Accounting Officer of Microvast Holdings, Inc. (the “Company”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1760689/000094787126000585/0000947871-26-000585-index.htm"}},{"accession":"0001539497-26-001624","ticker":null,"company_name":"BMO 2026-5C14 Mortgage Trust","filed_at":"2026-06-01T18:53:15+00:00","headline":"BMO 2026-5C14 transfers Compass Storage Whole Loan servicing to Benchmark 2026-V22","event_type":"other_material","sec_items":["1.01","9.01"],"materiality_score":0.35,"calibrated_materiality_score":0.35,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001539497-26-001624","json":"https://secwatch.observer/filing/0001539497-26-001624.json","markdown":"https://secwatch.observer/filing/0001539497-26-001624.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2063015/000153949726001624/0001539497-26-001624-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2063015/000153949726001624/n5711_x18-8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 8, 2026, Nektar Therapeutics (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”) having an aggregate offering price of up to $150,000,000 (the “Shares”), through Guggenheim Securities and Wainwright as its sales agents.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/0001193125-26-214976-index.htm","comparable_excerpt":"On March 25, 2026 (the “ Closing Date ”), BMO 2026-5C14 Mortgage Trust (the “ Issuing Entity ”) issued the BMO 2026-5C14 Mortgage Trust, Commercial Mortgage Pass-Through Certificates, Series 2026-5C14, pursuant to a Pooling and Servicing Agreement, dated as of March 1, 2026 (the “ Pooling and Servicing Agreement ”), between BMO Commercial Mortgage Securities LLC, as depositor, Midland Loan Services, a Division of PNC Bank, National Association, as master servicer, CWCapital Asset Management LLC, as special servicer, Pentalpha Surveillance LLC, as operating advisor and as asset representations reviewer, and Computershare Trust Company, National Association, as certificate administrator and as trustee.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2063015/000153949726001624/0001539497-26-001624-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}